Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Catapult Programme
Catapult Programme
Activities:
Hi Tech Manufacturing
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
MicrofluidX makes key collaboration for microfluidics platform
CPI, MicrofluidX and the Cell and Gene Therapy Catapult have collaborated to develop bioprocessing technology for the rapid scale-up of cell and gene therapies
Research & Development
Cell and Gene Therapy Catapult launches pluripotent stem cell collaboration
CiRA Foundation and the Catapult will combine their expertise to explore novel methods to characterise pluripotent stem cells for the manufacture of regenerative medicinal products
Matthew Durdy to spearhead CGT Catapult
Durdy will take up the role of Chief Executive Officer in April this year
Pharmaceutical
CGT Catapult works with UK university to host aseptic ATMP manufacturing course
Initiative with the Hertfordshire University aims to address the foreseeable skills gap in manufacturing cell and gene therapies as they near commercial scale manufacturing
Finance
Gene modulation newcomer recieves $667,000 for proof of concept
Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that it says overcomes the challenges associated with the technologies currently available
Recruitment
Cell and Gene Therapy Catapult to recruit new Chief Executive
Keith Thompson will retire in April 2020 having established the company in 2012
Design & Build
Cell and Gene Therapy Catapult doubles capacity at UK site
Expansion follows the success of first six cleanrooms built at the large-scale manufacturing centre in Stevenage
Subscribe now